BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220402
DTSTAMP:20260516T010209
CREATED:20211210T094616Z
LAST-MODIFIED:20211210T094922Z
UID:32479-1648512000-1648857599@www.pharmajournalist.com
SUMMARY:12th World ADC London
DESCRIPTION:12th Annual World ADC London\n29th March – 1st April 2022\nLondon \nThe ADC field is going from strength to strength\, further catalysed in 2021 by the approvals of Zynlonta and Tivdak respectively\, bringing the total number of commercially available ADCs to 11. \nReturning in-person in from 29th March – 1st April\, be part of the 12th Annual World ADC London and reconnect with 400+ of your peers at the forefront of ADC drug development. \nAfter in-depth research with key opinion leaders within the ADC field\, this is your most extensive programme to-date addressing the most pressing challenges facing ADC developers from discovery through to late phase manufacturing. \nTake a look at the brand-new agenda here! \nThe four-streamed\, four-day unrivalled programme with 75+ industry-leading speakers will equip you with the insights and connections to nourish your current pipelines of ADCs\, discover the next generation of non-traditional ADCs\, and confidently define your manufacturing processes. \nRegister now and join the likes of the likes of Daiichi Sankyo\, AstraZeneca\, ADC Therapeutics\, Seagen and many more to work collaboratively to overcome the distinct challenges ADC drug development holds and maximise the therapeutic window of ADCs.
URL:https://www.pharmajournalist.com/event/12th-world-adc-london/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220330
DTEND;VALUE=DATE:20220402
DTSTAMP:20260516T010209
CREATED:20220211T093912Z
LAST-MODIFIED:20220211T094005Z
UID:33197-1648598400-1648857599@www.pharmajournalist.com
SUMMARY:7th Innate Killer Summit 2022
DESCRIPTION:2021 was a game-changing year for the NK cell community. Positive clinical results have forced the field to wake up to the potential of these pioneering approaches. \nSupporting the field since its’ infancy\, the Innate Killer Summit returns for its 7th year as the leading\, industry-defining forum dedicated to advancing the field to achieve clinical success. \nSpanning the current drug development landscape\, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing\, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies. \nGet your copy of the 2022 agenda here. \nJoin over 200 experts to characterize and contrast cell sources\, supercharge combinations\, optimize CMC workflows\, examine expansion protocols for high-quality products at scale\, and move the field towards persistent\, scalable\, and cost-effective innate immune cell therapies. \nPromising unpublished data\, interactive discussion\, and engaging networking opportunities join this exclusive summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.
URL:https://www.pharmajournalist.com/event/7th-innate-killer-summit-2022/
LOCATION:Sheraton San Diego Hotel & Marina\, 1380 Harbor Island Drive\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220404
DTEND;VALUE=DATE:20220408
DTSTAMP:20260516T010209
CREATED:20211109T090819Z
LAST-MODIFIED:20211109T090819Z
UID:32034-1649030400-1649375999@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy for Muscular Disorders Summit
DESCRIPTION:Mitigating Toxicity & Revolutionizing Muscle Targeting \nThe 2nd Gene Therapy for Muscular Disorders Summit will be returning as an in-person event to Boston in April 2022\, to help gene therapy developers targeting muscular disorders to overcome safety and toxicity \nchallenges and effectively translate their programs into the clinic. \nHighlighting AAV and gene editing challenges for Duchenne’s (DMD)\, Limb-Girdle (LGMD)\, Pompe Disease\, X-Linked Myotubular Myopathy and other muscular disorders\, this industry-focused 4-day event will cover:  \n\nOvercoming immunogenicity challenges and mitigate toxicity with high doses\nOptimizing vector and promoter choice and design for more efficient delivery tomuscle targets\nDefining clinically meaningful muscular endpoints to successfully develop and safely deliver the optimal dose to their muscular targets\n\nJoin over 150 fellow industry experts to learn\, share and benchmark yourselves against your competitors\, and overcome the toxicity and dosage challenges hindering the progress of your gene therapy targeting the muscle. \nTo know more visit: https://ter.li/tbbaua
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-for-muscular-disorders-summit/
LOCATION:Hanson Wade\, Hyatt Regency Boston Downtown\, 1 Ave de Lafayette\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220405
DTEND;VALUE=DATE:20220408
DTSTAMP:20260516T010209
CREATED:20220110T223347Z
LAST-MODIFIED:20220111T091913Z
UID:32756-1649116800-1649375999@www.pharmajournalist.com
SUMMARY:Wet AMD & DME Drug Development Summit
DESCRIPTION:Accelerating the Development of Novel Anti-VEGF\, VEGF-independent Therapies & Drug Delivery Options To Reduce Clinical Burden\, Widen Therapeutic Index & Treatment Options for Non-responders \nThe second edition of the industry-led Wet AMD & DME Drug Development Summit will give comprehensive insight into the current and emerging angiogenesis-\, inflammatory-directed and anti-fibrotic drug development programmes for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD)\, diabetic retinopathy (DR) and diabetic macular edema (DME). \nThe 2022 Summit will include interactive presentations and panel discussions\, covering challenging questions for the whole research community such as: \n\nWhat are the future directions for anti-VEGF therapy to increase patient response rates\, prolong treatment durability and reduce clinical burden?\nWhere is the clinical success for targeting VEGF-independent pathways in this multifactorial disease?\nWhat interventions beyond anti-VEGF give treatment options for refractory or not optimally treated patients?\nHow are drug developers using various drug delivery methods – topical\, intravitreal\, suprachoroidal\, port delivery – to expand the therapeutic window?\nHow has optical coherence tomography (OCT) imaging\, including at-home diagnostic testing\, and artificial intelligence-enabled programming personalized wet AMD and DME treatment and supported clinical trials?\n\nAs the only industry-led forum solely dedicated to finding long-lasting therapeutic interventions for wet AMD and DME\, attendees will have the opportunity to review the multiple pathological mechanisms being actively targeted\, identify the latest clinical data from anti-VEGF suppression (antibody fragments\, delivery systems\, bispecific antibodies\, gene therapy)\, combinational approaches\, non- VEGF pathways (integrin and TKI’s) and VEGF-independent (such as targeting plasma kallikrein) therapies. \nMeet the leading ophthalmology drug developers from big pharma\, biotech and academia searching for treatment breakthroughs and actively gathering clinical evidence to demonstrate a favourable benefit/risk ratio for future products to regulators\, clinicians and payers. \nJoin us next April to hear their latest clinical development programs and identify future portfolio strategies for your organisation. \nTo know more visit: https://ter.li/m98rr7
URL:https://www.pharmajournalist.com/event/wet-amd-dme-drug-development-summit/
LOCATION:Embassy Suites by Hilton Boston Logan Airport\, 207 Porter St.\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220407
DTEND;VALUE=DATE:20220408
DTSTAMP:20260516T010209
CREATED:20211208T111909Z
LAST-MODIFIED:20220309T194319Z
UID:32412-1649289600-1649375999@www.pharmajournalist.com
SUMMARY:Purify’22
DESCRIPTION:PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nThe maiden PURIFY’19 edition was a huge hit amongst fellow chromatographers\, steered by our esteemed advisory board. \nPURIFY’19 was attended by 113 delegates across 19 cities\, spread across 51 corporates with 14 speakers and 6 display zones! \nSo\, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more\, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related. \nDownload Brochure
URL:https://www.pharmajournalist.com/event/purify22/
LOCATION:ITC Kohenur\,Hyderabad
ORGANIZER;CN="Custage Marketing Solutions LP":MAILTO:rashi@custage.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220412
DTEND;VALUE=DATE:20220415
DTSTAMP:20260516T010209
CREATED:20220114T093101Z
LAST-MODIFIED:20220114T093101Z
UID:32768-1649721600-1649980799@www.pharmajournalist.com
SUMMARY:LNP Formulation & Process Development Summit
DESCRIPTION:Embrace Technology Innovations to Optimize LNP Formulation\, Alternative LNP Raw Materials\, Process Control to Achieve Seamless Scale-Up\, Compliance & Cost Effectiveness  \nThe inaugural LNP Formulation & Process Development Summit is the industry’s first forum dedicated to bringing together drug developers within the LNP field to share the latest scientific breakthroughs on formulation and process development. Across 3 days\, you will address challenges and seek solutions to help you optimize your formulation to enhance stability\, efficacy\, and better characterization for drug product quality. This is your chance to explore the use of alternative polymer lipids to maximize scalability and moving towards cGMP manufacturing for pipeline progression. \nThe global nanopharmaceutical drugs market\, catalyzed by the success of Pfizer/BioNTech and Moderna’s mRNA vaccines\, is poised to reach US$82.7 billion by 2027. The demand of novel LNP to support the delivery of oligonucleotide and nucleic acid-based therapies is growing at an exponential rate. With the overwhelming possibilities of lipid nanoparticles\, there are key questions on formulation\, process development and scalability that still need to be answered. There has been no better time to join forces and help accelerate the development of truly remedial LNP therapeutics. \nTo know more visit: https://ter.li/8hrml3
URL:https://www.pharmajournalist.com/event/lnp-formulation-process-development-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220419
DTEND;VALUE=DATE:20220422
DTSTAMP:20260516T010209
CREATED:20211206T123933Z
LAST-MODIFIED:20211206T123933Z
UID:32385-1650326400-1650585599@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy Medical Affairs Summit
DESCRIPTION:Transforming Traditional Medical Affairs \nOptimize Medical Affairs Proactive Engagements and Education Initiatives to Successfully Launch the Next Generation of Gene Therapy Products  \nThe 2nd Annual Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role Medical Affairs plays in delivering gene therapies to patients. This is your opportunity to take inspiration from Medical Affairs leaders of the gene therapy world and learn how traditional Medical Affairs approaches are being transformed to meet the unique challenges associated with gene therapy drug development. \nGain actionable insights from first-to-market pioneers\, who will share how to engage effectively with internal clinical\, commercial and regulatory teams as well as external HCPs\, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex\, high priced Gene Therapy products. \nThe summit will provide a dedicated platform that discusses the role and value of Medical Affairs across each of the phases of the gene therapy development cycle. We will delve into the unique challenges encountered when working with gene therapies\, from adapting to the clinical realities of the rare disease space\, to handling long-term follow up and post-launch regulatory scrutiny\, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before. \nTo know more visit: https://ter.li/xciowp
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-medical-affairs-summit/
LOCATION:Westin Boston Seaport Hotel\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220421
DTEND;VALUE=DATE:20220701
DTSTAMP:20260516T010209
CREATED:20220425T094247Z
LAST-MODIFIED:20220519T120013Z
UID:33903-1650499200-1656633599@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:This year CPhI & P-MEC China returns as a SMART event\, combining 2 months of online event with a 3-day in-person event to help you connect for an extended period. \n \n“Virtual Expo Connect”\, to be held from 21st April – 30th June 2022\, is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals. \nPowered by PharmaSources.com\, Virtual Expo Connect builds the online platform adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nTo know more visit: https://www.pharmasources.com/vec2022
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect-2/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:Yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220425
DTEND;VALUE=DATE:20220427
DTSTAMP:20260516T010209
CREATED:20211206T115226Z
LAST-MODIFIED:20211206T115226Z
UID:32376-1650844800-1651017599@www.pharmajournalist.com
SUMMARY:SMi’s 9th Annual Conference Pre-Filled Syringes East Coast
DESCRIPTION:SMi’s 9th Annual Conference\nPre-Filled Syringes East Coast\nMain Conference: April 25 – 26\, 2022 | Workshops: April 27\, 2022 \nSheraton Boston Hotel\, Boston\, MA\, USA \nwww.pfsamericas.com/pharmajournalistwl \nSponsors are: SCHOTT\, ZEON \nExhibitors: Owen Mumford Pharmaceutical Services\, PHC Corporation\, POLYPLASTICS- TOPAS\, Weiss-Aug Group \nDevice innovations\, connected delivery and regulatory guidance for advanced parenteral systems \nThe global pre-filled syringes market was valued at $1139.6 million in 2020 and with the rapid growth of the industry\, is expected to grow at a CAGR of 8.95% up to 2027. With that in mind\, the 9th annual Pre-Filled Syringes East Coast conference will bring together leading industry experts representing big pharma and device developers to discuss the key drivers accelerating the expansion of the industry. \nThe past year has seen significant developments in the injectables landscape with the rapid introduction and development of vaccines in response to the pandemic\, updates in regulations including the EU MDR and FDA guidance on bridging studies\, and increasing industry acceptance of connectivity to aid the user experience. As part of SMi’s leading injectable series\, the 2022 conference will provide an exclusive insight into the latest developing technologies for device design\, advances in parenteral device platforms and development\, insights into growing integration of digital health and deep dives into recent case studies on novel delivery systems. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nVisit the website at: www.pfsamericas.com/pharmajournalistwl \nChair for 2022: \nGretchen Vandal\, Sr. Director\, Head of Global Regulatory Affairs – Devices and Combination Products\, Takeda \nGuest FDA Speaker: \n\nJohn Barr Weiner\, Associate Director for Policy and Product Classification Office\, Office of Combination Products FDA\n\n Featured 2022 Speakers Include: \n\nJoyce Zhao\, Associate Director\, Combination Product\, Takeda\nSuzette Roan\, Associate VP and Head of Global Device Regulatory Affairs\, Sanofi US\nChristine lynn lanning\, Distinguished Scientist\, Device Area Leader\, Merck\nHeather l. Guerin\, Associate Director\, Regulatory Affairs – CMC\, JanssenTieming Ruan\, Senior Director of Device Development\, Alexion Pharmaceuticals\nJohn Schalago\, Executive Director\, Senior Global Program Director Regulatory Affairs\, Novartis\nGretchen Piwinski\, Manager\, Combination Product Laboratories\, Regeneron\nMichael Song\, Associate Director\, Takeda\nDeep S Bhattacharya\, Senior Scientist\, Drug Product Development and Design\, Pfizer\n\nBENEFITS OF ATTENDING: \n\nExplore the latest developments in innovative technologies for device design accelerating the path to self-administration\nAssess the evolving regulatory landscape for pre-filled syringes and discuss approaches to work with regulators as guidance is updated\nEngage in panel discussions with industry leaders to navigate the accelerating digital health landscape for combination products and drug delivery systems\nUnderstand the landscape of delivery for novel drug products and key considerations to overcome challenges in CCI\n\nView the full agenda and speaker line-up online: www.pfsamericas.com/pharmajournalistwl \nWho should Attend: \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers\n\nEARLY-BIRD RATES:  \n\nBOOK BY 17th DECEMBER AND SAVE $400\nBOOK BY 31st JANUARY AND SAVE $200\nBOOK BY 28TH FEBRUARY AND SAVE $100\n\nRegistrations can be made on the event website at: www.pfsamericas.com/pharmajournalistwl
URL:https://www.pharmajournalist.com/event/smis-9th-annual-conference-pre-filled-syringes-east-coast/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220425
DTEND;VALUE=DATE:20220428
DTSTAMP:20260516T010209
CREATED:20211217T132942Z
LAST-MODIFIED:20211217T132942Z
UID:32542-1650844800-1651103999@www.pharmajournalist.com
SUMMARY:2nd Chronic HBV Drug Development Summit
DESCRIPTION:With a tight focus on late translational to phase II clinical progress\, the 2nd Chronic HBV Drug Development Summit returns in person as the definitive industry forum to advance combination therapy and achieve functional cure in hepatitis B virus. \nDedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms\, this industry-orientated forum is timely positioned after EASL to reset standards after the latest readouts. \nFrom transformative advances in establishing synergistic combination regimens\, to navigating clinical endpoints and stopping points\, and illuminating the role of immunotherapy to attain durable functional cure\, don’t miss your chance to join the conversation. \nHarness actionable insights across 3 days of exclusive content from 20+ scientific experts including Gilead Sciences\, Vir Biotechnology\, VBI Vaccines\, Altimmune\, Drug Farm\, Replicor and many more to guide your strategic decisions and drive clinical progress. \nJoin us in Boston to forge successful industry collaborations in combination therapy for chronic HBV. \nTo know more visit: https://ter.li/o1utyk
URL:https://www.pharmajournalist.com/event/2nd-chronic-hbv-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220425
DTEND;VALUE=DATE:20220428
DTSTAMP:20260516T010209
CREATED:20211217T154450Z
LAST-MODIFIED:20211217T154530Z
UID:32594-1650844800-1651103999@www.pharmajournalist.com
SUMMARY:Novel Format Conjugates Summit
DESCRIPTION:The inaugural Novel Format Conjugates Summit exclusively focuses on the common challenges across early research and development of next generation Non-Traditional ‘ADCs’\, or alternative format conjugates approaches for oncology and beyond. This meeting delves into the different technologies of these novel-format conjugates\, exploring how conjugation chemistry is affected for different kinds of therapeutic modalities\, and the impact an alternative format ADC has on targeting. \nAs we look to the future of drug development of novel conjugates\, you will get the chance to hear the cutting-edge science accelerating the development of Bispecific ADCs\, Radio-conjugates\, ISACs\, SMDCs\, Probody conjugates\, Liposomal drug conjugates\, Oligonucleotide conjugates and many more. \nEngage in cross-industry discussions and presentations from over 20 expert speakers across 3 unmissable days and equip yourself with the tools to develop novel format ADCs with an improved therapeutic potential so we can bring more drugs to patients of unmet needs. \nTo know more visit: https://ter.li/0811lm
URL:https://www.pharmajournalist.com/event/novel-format-conjugates-summit/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220425
DTEND;VALUE=DATE:20220428
DTSTAMP:20260516T010209
CREATED:20220125T123012Z
LAST-MODIFIED:20220125T123113Z
UID:32954-1650844800-1651103999@www.pharmajournalist.com
SUMMARY:3rd Supply Chain and Logistics for Cell Therapies Summit
DESCRIPTION:Keen to unite with your #celltherapy supply chain community and gain actionable insights for streamlining logistics\, implementing digital platforms and optimizing patient operations to establish a reliable global delivery of cell therapies? \nThen look no further! The 3rd Supply Chain & Logistics for Cell Therapies Summit is back and taking place in-person for the first time this 25-27 April 2022! \nView the full 3-day agenda here: https://ter.li/yp10r2 \n2022 Agenda Overview: \nWith exclusive presentations and interactive talks on key industry challenges\, gain valuable takeaways from leaders in the field from GlaxoSmithKline\, Legend Biotech\, Iovance\, Gamida Cell\, and more. Discuss standardization\, review digital system implementation\, prepare for upscaling and optimize cryopreservation in person with like-minded supply chain professionals all to maximize efficiency and create a patient-centric end-to-end system. \nDownload the full event guide to learn more about our speakers\, agenda topics\, and face-to-face networking opportunities. https://ter.li/yp10r2
URL:https://www.pharmajournalist.com/event/3rd-supply-chain-and-logistics-for-cell-therapies-summit/
LOCATION:Crowne Plaza Boston – Woburn\, an IHG Hotel\, 15 Middlesex Canal Park Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220429
DTSTAMP:20260516T010209
CREATED:20211213T100512Z
LAST-MODIFIED:20220316T101306Z
UID:32486-1650931200-1651190399@www.pharmajournalist.com
SUMMARY:2nd Ligase Targeting Drug Development Summit
DESCRIPTION:Whilst the exploiting of this therapeutic modality surges through biopharma and academia\, it is essential that we unlock the fundamental challenges within this industry\, as this remains a key factor determining success of degraders in the clinic. \n \nThe 2nd Ligase Targeting Drug Development Summit returns to Boston in April again uniting industry frontiers and leading minds\, as together we discuss\, update\, and learn how to successfully hijack ligases for therapeutic application\, and uncover a critical piece of the puzzle in realizing the full potential of this therapeutic approach. \nFilling the gap of an industry-led ubiquitin discussion\, we again provide an unrivalled forum to unite leading biopharmaceutical giants\, alongside key academics\, to share unseen data\, collaborative efforts and discuss next steps to successfully select\, validate and translate E3’s into a viable therapy. \nJoin us in Boston to expand your understanding of the ever-broadening ligases field and the fast-improving chemical biology tools to seize the therapeutic value of Ubiquitin E3 ligases and differentiate your pipelines. \nTo Know more visit: https://ter.li/rm8y7d
URL:https://www.pharmajournalist.com/event/2nd-ligase-targeting-drug-development-summit/
LOCATION:Online\, EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220428
DTSTAMP:20260516T010209
CREATED:20220117T082710Z
LAST-MODIFIED:20220127T121445Z
UID:32823-1650931200-1651103999@www.pharmajournalist.com
SUMMARY:Reuters Events: Digital Health 2022
DESCRIPTION:Join the world’s leading forum for advancing the delivery of digital care \nDigital Health’s deployment has been as fast as it has wide. Overnight it has become the central focus for hospitals\, clinics and health plans across the nation. The result? Workflows are more complicated than ever. We’re failing on patient engagement. And we still lack a clearly defined digital care payment infrastructure. \nNow is the moment to tackle inefficiencies in our use of digital health or risk sub-optimal becoming the new norm. We must not squander the biggest opportunity for the industry’s advancement in half a century. \nThat’s why we’ve created Reuters Events Digital Health – the place where the standard is set by 300+ executives for the delivery of quality virtual\, predictive\, affordable and equitable care. Our world-leading forum is where leaders of health systems\, payers\, policy makers\, pharma and health tech converge to realize the transformative potential of technology in healthcare.
URL:https://www.pharmajournalist.com/event/reuters-events-digital-health-2022/
LOCATION:Mission Bay Resort\, San Diego\, California
ORGANIZER;CN="Reuters Events":MAILTO:jack.tiplady@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220429
DTSTAMP:20260516T010209
CREATED:20220125T093551Z
LAST-MODIFIED:20220125T093551Z
UID:32942-1650931200-1651190399@www.pharmajournalist.com
SUMMARY:5th Neoantigen Summit Europe
DESCRIPTION: The 5th Neoantigen Summit Europe\, the definitive industry meeting for uncovering the full potential of neoantigens in creating individualised neoantigen vaccines is returning in person! \nFrom understanding the latest clinical insights to reviewing vaccines post-COVID\, our 35+ expert speakers and 3-day agenda developed alongside #Vaccibody\, #Gritstonebio\, #Targovax\, #Vaximm\, #Immunetune and #OdimmaTherapeutics will help you advance your pipeline to successfully weaponise neoantigens for anti-tumour treatment. \nJoin 100+ colleagues and take on the next frontier in neoantigen identification and vaccine manufacturing. \nKey speakers include: Agnete Fredriksen\, Chief Innovation & Strategy Officer\, Nykode Therapeutics | Barbara Loesch\, Head of Technology and Innovation\, Medigene |Jessica Matta\, Co-Founder & Chief Executive Officer & Chief Scientific Officer\, Odimma therapeutics | Andrew Allen\, CEO\, Gritstone bio | Peter Sondermann\, CEO\, Tacalyx GmbH |Sijme Zeilemaker\, Chief Executive Officer\, Immunetune \nFind out more in the event guide here: https://ter.li/gulg78 \nVisit the official event website here: https://ter.li/s89k61
URL:https://www.pharmajournalist.com/event/5th-neoantigen-summit-europe/
LOCATION:Leonardo Royal Amsterdam\, Paul van Vlissingenstraat 24\, Amsterdam\, 1096 BK\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220429
DTSTAMP:20260516T010209
CREATED:20220201T115212Z
LAST-MODIFIED:20220201T115212Z
UID:33082-1650931200-1651190399@www.pharmajournalist.com
SUMMARY:6th R&D Sourcing & Procurement Summit in Pharma
DESCRIPTION:We are excited for the 6th Advanced R&D Procurement & Sourcing in Pharma Summit returning to Boston in April\, reuniting senior leaders to share their stories and lessons learned\, and how they implement strategic sourcing to optimize spending and mitigate risks. \nAs the one and only community dedicated to 100+ R&D procurement\, category management\, and sourcing professionals\, this is your must-attend conference in 2022 to benchmark your SOPs against your peers and stay at the forefront of technology to streamline your procurement processes. Leave this meeting with practical tips to drive scientific innovations with sustainability\, optimized spend and strengthened vendor relationships! \nYour Unmissable Spotlight Case Studies In 2022: \n\nEstablish robust external supplier relationship models to advance your pipeline development with Betrand Rosier\, Global Procurement Head\, Sanofi\nRebrand procurement to be your scientists’ best business partner with Gerard Cardillo\, Vice President\, Global Procurement\nExplore lessons learned from COVID including strategic investing with Sean Cumbie\, Vice President\, Global Sourcing & Procurement\, NOVAVAX\nDevelop sourcing & procurement strategies at lightspeed with James Tornos\, Vice President\, Sourcing & Enterprise Services – Research\, Development and Medical Procurement\, Pfizer\nDeep-dive into driving D&I initiatives\, both within companies and through supplier diversity initiatives in an exclusive\, interactive workshop led by Manuele Burdese\, Senior Director\, Head of Business Insights & Analytics Strategic Sourcing & Procurement\, Bristol Myers Squibb\, Tom Thattacherry\, Head\, Supplier Diversity\, Genentech\n\nTo find out how you and your team can get involved download your free event guide or get in touch.
URL:https://www.pharmajournalist.com/event/6th-rd-sourcing-procurement-summit-in-pharma/
LOCATION:The Bostonian Boston\, 26 NORTH STREET\, BOSTON\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:monica.mojumder-chan@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220427
DTEND;VALUE=DATE:20220429
DTSTAMP:20260516T010209
CREATED:20220131T115758Z
LAST-MODIFIED:20220131T115758Z
UID:33066-1651017600-1651190399@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference
DESCRIPTION:SMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference\nConference: 27 – 28 April 2022\nWorkshops: 29 April 2022\nBoston\, MA\, USA\nhttp://www.microbiologyeastcoast.com/PJwl \nSponsored by: Bioscience International\, Associates of Cape Cod and Microbiologics \nChaired by: Jim Polarine\, Senior Technical Service Manager\, Head of Microbiology & Sterile Technology\, STERIS Corporation \nHarnessing existing methods and novel tools in microbial control to assure continuity in product quality and patient safety \nSMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference is taking place in Boston on April 27-28\, 2022\, with interactive workshops on April 26\, 2022. \nMicrobiology remains an essential tool in reducing microbial growth in the manufacture of pharmaceuticals\, to detect and eliminate microorganisms that would pose a risk to patients and jeopardise product batches. \nEnsuring the sterility of the finished product continues to be one of the most critical aspects of drug development\, however an array of factors are also sustaining new growth and transformation in this field. The regulatory landscape is changing\, firstly with the preparation of Annex 1\, in addition to increasing requirements pertaining to data integrity. Light is being shed on recent product recalls for mould contamination\, and infection outbreaks serve as a reminder to pay more attention to these overlooked organisms\, as well as considerations towards container closure integrity testing which is being increasingly deployed to block microbe movement. \nOn top of this\, the developing integration of automation and robotics into the manufacturing pipeline\, as well as the increased need for more rapid microbiology methods brought about in part by the surge in ATMPs\, are all highlighting the necessity of the field in Pharma.  \nThis industry is ever expanding\, join leading experts in 2022 to discuss and analyse the latest advances and challenges surrounding Pharmaceutical Microbiology. Network with industry professionals\, discuss revisions in regulatory and guidance documents\, and gain a deeper insight into this corner of the field.\nEvent Hashtag: #SMiPharmaMicroEC  \nKey Highlights for 2022:  \n\nReview implementation guidance and validation for efficient disinfectant efficacy programs\nUncover principles in best-practice and the benefits of a robust contamination control strategy\nAddress fungal mould contamination and risk-based tools to tackle spore spreading\nDelve into the sterility assurance assessment and holistic closure integrity testing\nExplore the impact of the ongoing pandemic and the changing face of the pharma industry\nUnderstand new unique case studies\, from contamination control as it relates to microbiome products\, to risk-based assessments of traditional microbiological tests\n2 Interactive Pre-Conference Workshops on April 26\, 2022\n\nInteractive Workshops: \nWorkshop A: Risk Assessment and Cleaning Validation \nWorkshop Leader: Fred Ohsiek\, SME\, Cleaning Validation\, North America \nWorkshop B: USP Microbiology 2022 – Keeping Up with Standards \nWorkshop Leader: Donald Singer\, Chair\, General Chapters – Microbiology Expert Committee\, US Pharmacopeia and Ecolab Life Sciences \nView the full agenda: http://www.microbiologyeastcoast.com  \nWHO SHOULD ATTEND? \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist\, Drug Substance External Manufacturer\, QC Scientists\, Heads of Quality\, Business Development Manager\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist
URL:https://www.pharmajournalist.com/event/smis-5th-annual-pharmaceutical-microbiology-east-coast-conference/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR